Genome-wide DNA methylation risk scores for schizophrenia derived from blood and brain tissues further explain the genetic risk in patients stratified by polygenic risk scores for schizophrenia and bipolar disorder.

Kazutaka OhiMihoko ShimadaMidori SodaDaisuke NishizawaDaisuke FujikaneKentaro TakaiAyumi KuramitsuYukimasa MutoShunsuke SugiyamaJunko HasegawaKiyoyuki KitaichiKazutaka IkedaToshiki Shioiri

Published in: BMJ mental health (2024)

These findings suggest that the MRS is a potential genetic marker in understanding SZ, particularly in patients with a genetic SZ risk.

Keyphrases

bipolar disorder
genome wide
dna methylation
end stage renal disease
major depressive disorder
gene expression
newly diagnosed
chronic kidney disease
ejection fraction
risk assessment
multiple sclerosis
peritoneal dialysis